TY - JOUR
T1 - Association between preoperative administration of gabapentinoids and 30-day hospital readmission
T2 - A retrospective hospital registry study.
AU - Wachtendorf, Luca J.
AU - Schaefer, Maximilian Sebastian
AU - Santer, Peter
AU - Azimaraghi, Omid
AU - Obeidat, Salameh Sameh
AU - Friedrich, Sabine
AU - Zucco, Liana
AU - Woo, Albert
AU - Nabel, Sarah
AU - Sundar, Eswar
AU - Eikermann, Matthias
AU - Ramachandran, Satya Krishna
N1 - Funding Information:
We are grateful to Karuna Wongtangman, MD for making non-author contributions with her helpful suggestions during the writing of this manuscript. L.J.W.: Study concept and design, data collection, data analysis, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. M.S.S.: Study concept and design, data collection, data analysis, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. P.S.: Study concept and design, data collection, data analysis, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. O.A.: Study concept and design, data collection, data analysis, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. S.S.O.: Interpretation of data, drafting the manuscript, final approval of the version to be submitted. S.F.: Data collection, interpretation of data, critical revision of the manuscript, final approval of the version to be submitted. L.Z.: Interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. A.W.: Data collection, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. S.N.: Data collection, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. E.S.: Interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. M.E.: Study concept and design, data collection, data analysis, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. S.K.R.: Study concept and design, data collection, data analysis, interpretation of data, drafting the manuscript, critical revision of the manuscript, final approval of the version to be submitted. All authors approved of the final manuscript version to be published and agree to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The manuscript's guarantor is M.E. He affirms that this manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted. This study was funded by Jeffrey and Judy Buzen in an unrestricted grant to M.E. The funders had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Due to the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject research and confidentiality may be sent to M.E. at meikermann@montefiore.org. The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide license to the publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the contribution, ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the contribution, iii) create any other derivative work(s) based on the contribution, iv) to exploit all subsidiary rights in the contribution, v) the inclusion of electronic links from the contribution to third party material where-ever it may be located; and, vi) license any third party to do any or all of the above. M.E. has received grants for investigator-initiated trials not-related to this manuscript from Merck & Co. and serves as a consultant in the advisory board of Merck & Co. during the conduct of the study. S.K.R. has received scientific consulting fees from Fresenius Kabi USA not related to this study. L.J.W. M.S.S. P.S. O.A. S.S.O. S.F. L.Z. A.W. S.N. and E.S. have no conflicts of interest. We are grateful to Karuna Wongtangman, MD for making non-author contributions with her helpful suggestions during the writing of this manuscript.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/10
Y1 - 2021/10
N2 - Study objective: To evaluate the effectiveness of preoperative gabapentinoid administration. Design: Retrospective hospital registry study. Setting: Tertiary referral center (Boston, MA). Patients: 111,008 adult non-emergency, non-cardiac surgical patients between 2014 and 2018. Interventions: Preoperative administration of gabapentinoids (gabapentin or pregabalin). Measurements: We tested the primary hypothesis that preoperative gabapentinoid use was associated with lower odds of hospital readmission within 30 days. Contingent on this hypothesis, we examined whether lower intraoperative opioid utilization mediated this effect. Secondary outcome was postoperative respiratory complications. Main results: Gabapentinoid administration was associated with lower odds of readmission (adjusted odds ratio [ORadj] 0.80 [95% CI, 0.75–0.85]; p < 0.001). This effect was in part mediated by lower intraoperative opioid utilization in patients receiving gabapentinoids (8.2% [2.4–11.5%]; p = 0.012). Readmissions for gastrointestinal disorders (ORadj 0.74 [0.60–0.90]; p = 0.003), neuro-psychiatric complications (ORadj 0.66 [0.49–0.87]; p = 0.004), non-surgical site infections (ORadj 0.68 [0.52–0.88; p = 0.004) and trauma or poisoning (ORadj 0.25 [0.16–0.41]; p < 0.001) occurred less frequently in patients receiving gabapentinoids. The risk of postoperative respiratory complications was lower in patients receiving gabapentinoids (ORadj 0.77 [0.70–0.85]; p < 0.001). Lower doses of pregabalin (< 75 mg) and gabapentin (< 300 mg) compared to both, no and high-dose administration of gabapentinoids, were associated with a lower risk of postoperative respiratory complications (ORadj 0.61 [0.50–0.75]; p < 0.001 and ORadj 0.70 [0.53–0.92]; p = 0.012, respectively). These lower gabapentinoid doses prevented 30-day readmission (ORadj 0.74 [0.65–0.85]; p < 0.001). The results were robust in several sensitivity analyses including surgical procedure defined subgroups and patients undergoing ambulatory surgery. Conclusions: The preoperative use of pregabalin and gabapentin, up to doses of 75 and 300 mg respectively, mitigates the risks of hospital readmission and postoperative respiratory complications which can in part be explained by lower intraoperative opioid use. Further research is warranted to elucidate mechanisms of the preventive action.
AB - Study objective: To evaluate the effectiveness of preoperative gabapentinoid administration. Design: Retrospective hospital registry study. Setting: Tertiary referral center (Boston, MA). Patients: 111,008 adult non-emergency, non-cardiac surgical patients between 2014 and 2018. Interventions: Preoperative administration of gabapentinoids (gabapentin or pregabalin). Measurements: We tested the primary hypothesis that preoperative gabapentinoid use was associated with lower odds of hospital readmission within 30 days. Contingent on this hypothesis, we examined whether lower intraoperative opioid utilization mediated this effect. Secondary outcome was postoperative respiratory complications. Main results: Gabapentinoid administration was associated with lower odds of readmission (adjusted odds ratio [ORadj] 0.80 [95% CI, 0.75–0.85]; p < 0.001). This effect was in part mediated by lower intraoperative opioid utilization in patients receiving gabapentinoids (8.2% [2.4–11.5%]; p = 0.012). Readmissions for gastrointestinal disorders (ORadj 0.74 [0.60–0.90]; p = 0.003), neuro-psychiatric complications (ORadj 0.66 [0.49–0.87]; p = 0.004), non-surgical site infections (ORadj 0.68 [0.52–0.88; p = 0.004) and trauma or poisoning (ORadj 0.25 [0.16–0.41]; p < 0.001) occurred less frequently in patients receiving gabapentinoids. The risk of postoperative respiratory complications was lower in patients receiving gabapentinoids (ORadj 0.77 [0.70–0.85]; p < 0.001). Lower doses of pregabalin (< 75 mg) and gabapentin (< 300 mg) compared to both, no and high-dose administration of gabapentinoids, were associated with a lower risk of postoperative respiratory complications (ORadj 0.61 [0.50–0.75]; p < 0.001 and ORadj 0.70 [0.53–0.92]; p = 0.012, respectively). These lower gabapentinoid doses prevented 30-day readmission (ORadj 0.74 [0.65–0.85]; p < 0.001). The results were robust in several sensitivity analyses including surgical procedure defined subgroups and patients undergoing ambulatory surgery. Conclusions: The preoperative use of pregabalin and gabapentin, up to doses of 75 and 300 mg respectively, mitigates the risks of hospital readmission and postoperative respiratory complications which can in part be explained by lower intraoperative opioid use. Further research is warranted to elucidate mechanisms of the preventive action.
KW - Complications
KW - Gabapentin
KW - Gabapentinoids
KW - Opioids
KW - Postoperative respiratory complications
KW - Pregabalin
KW - Readmission
UR - http://www.scopus.com/inward/record.url?scp=85108112572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108112572&partnerID=8YFLogxK
U2 - 10.1016/j.jclinane.2021.110376
DO - 10.1016/j.jclinane.2021.110376
M3 - Article
C2 - 34098392
AN - SCOPUS:85108112572
SN - 0952-8180
VL - 73
JO - Journal of Clinical Anesthesia
JF - Journal of Clinical Anesthesia
M1 - 110376
ER -